Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Other Non Operating Income (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Other Non Operating Income for 8 consecutive years, with -$1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non Operating Income fell 363.1% to -$1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.3 million, a 55.58% decrease, with the full-year FY2024 number at $33.3 million, up 2656.74% from a year prior.
  • Other Non Operating Income was -$1.1 million for Q3 2025 at Precision Biosciences, up from -$1.6 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $12.8 million in Q1 2024 to a low of -$7.3 million in Q4 2022.
  • A 5-year average of $1.3 million and a median of $96000.0 in 2023 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: plummeted 6270.83% in 2022, then soared 8861.46% in 2024.
  • Precision Biosciences' Other Non Operating Income stood at $2.2 million in 2021, then plummeted by 428.31% to -$7.3 million in 2022, then soared by 120.02% to $1.5 million in 2023, then soared by 691.96% to $11.5 million in 2024, then plummeted by 109.58% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Other Non Operating Income are -$1.1 million (Q3 2025), -$1.6 million (Q2 2025), and $1.5 million (Q1 2025).